Back HIV-Related Conditions Neurocognitive

Neurocognitive Problems

ICAAC 2013: Switching from Atripla to Complera Reduces Central Nervous System Side Effects

People who switched single-tablet regimens from Atripla (efavirenz/tenofovir/emtricitabine) to Complera (rilpivirine/tenofovir/emtricitabine) maintained viral load suppression and saw improvement in central nervous system (CNS) side effects such as abnormal dreams and depression, according to a late-breaking poster presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this month in Denver. Other studies looked at the safety and efficacy of Complera among women and black patients.

alt

Read more:

ICAAC 2013: Depression Linked to Detectable HIV in Cerebrospinal Fluid

People who experience episodes of major depressive disorder (MDD) are significantly more likely to have detectable HIV in their cerebral-spinal fluid (CSF), according to an analysis of the large CHARTER study presented as a late-breaker poster at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver.

alt

Read more:

Exercise Linked to Less Cognitive Impairment Among People with HIV

HIV positive people who recently engaged in physical exercise were about half as likely to show signs of neurocognitive impairment -- including impaired working memory and slower information processing -- as those who did not, according to a study published in the August 10, 2013, advance edition of the Journal of Neurovirology.

alt

Read more:

Neurocognitive Impairment Common Among Youth with HIV

Approximately two-thirds of HIV positive young adults showed evidence of HIV-associated neurocognitive disorders (HAND), including impaired memory and fine motor control, according to a report in the August 21, 2013, advance edition of the Journal of Adolescent Health.

alt

Read more:

CROI 2013: Researchers Look at Neurological Complications among People with HIV

Data from a small, yet well-designed trial to evaluate whether particular antiretroviral therapy (ART) regimens penetrate the central nervous system (CNS) and enhance neurocognitive performance were among several interesting findings regarding neurological complications among people with HIV presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta. Another study looked at similarities between Alzheimer's disease and neurocognitive impairment in people with HIV.

alt

Read more: